Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB105 intrathecal multiple-ascending-dose study in adults with ALS
NL-OMON52649Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Sep 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BIIB105 in amyotrophic lateral sclerosis (ALS) (12 cohorts), sponsored by Biogen. Primary endpoints: Number of participants with adverse events and Number of participants with serious adverse events. Started Sep 2020; status: active, not recruiting.
02
Drugs
BIIB105
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON52649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52649.